{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T16:38:19Z","timestamp":1793378299273,"version":"4.5.0"},"reference-count":241,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100006402","name":"Fasa University of Medical Science","doi-asserted-by":"publisher","award":["402125"],"award-info":[{"award-number":["402125"]}],"id":[{"id":"10.13039\/501100006402","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.intimp.2024.113544","type":"journal-article","created":{"date-parts":[[2024,11,20]],"date-time":"2024-11-20T05:18:03Z","timestamp":1732079883000},"page":"113544","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":37,"special_numbering":"C","title":["Novel targets for mucosal healing in inflammatory bowel disease therapy"],"prefix":"10.1016","volume":"144","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-1097-0274","authenticated-orcid":false,"given":"Pardis","family":"Mansouri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pegah","family":"Mansouri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esmaeil","family":"Behmard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sohrab","family":"Najafipour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amin","family":"Kouhpayeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9537-239X","authenticated-orcid":false,"given":"Akbar","family":"Farjadfar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.intimp.2024.113544_b0005","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1186\/s12967-021-02909-z","article-title":"Characterization of terminal-ileal and colonic Crohn\u2019s disease in treatment-na\u00efve paediatric patients based on transcriptomic profile using logistic regression","volume":"19","author":"Park","year":"2021","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.intimp.2024.113544_b0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2022.109545","article-title":"Combination therapy in inflammatory bowel disease: Current evidence and perspectives","volume":"114","author":"Dai","year":"2023","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.intimp.2024.113544_b0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2022.109230","article-title":"Repurposing metformin as a potential treatment for inflammatory bowel disease: evidence from cell to the clinic","volume":"112","author":"Wanchaitanawong","year":"2022","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.intimp.2024.113544_b0020","doi-asserted-by":"crossref","first-page":"221","DOI":"10.3181\/00379727-65-15917P","article-title":"Lysozyme in chronic ulcerative colitis","volume":"65","author":"Meyer","year":"1947","journal-title":"Proc. Soc. Exp. Biol. Med."},{"key":"10.1016\/j.intimp.2024.113544_b0025","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/493012","article-title":"Inflammatory bowel disease: an overview of immune mechanisms and biological treatments","volume":"2015","author":"De Mattos","year":"2015","journal-title":"Mediators Inflamm"},{"key":"10.1016\/j.intimp.2024.113544_b0030","first-page":"1459","article-title":"Rectal insulin instillation inhibits inflammation and tumor development in chemically induced colitis","volume":"12","author":"Yassin","year":"2018","journal-title":"Journal of Crohn\u2019s and Colitis"},{"key":"10.1016\/j.intimp.2024.113544_b0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2021.103758","article-title":"Targeting uPA-uPAR interaction to improve intestinal epithelial barrier integrity in inflammatory bowel disease","volume":"75","author":"Cheng","year":"2022","journal-title":"EBioMedicine"},{"key":"10.1016\/j.intimp.2024.113544_b0040","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.829525","article-title":"The emerging role of bile acids in the pathogenesis of inflammatory bowel disease","volume":"13","author":"Thomas","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2024.113544_b0045","article-title":"Intestinal Barrier and Permeability in Health, Obesity and NAFLD","volume":"10","author":"Portincasa","year":"2022","journal-title":"Biomedicines"},{"key":"10.1016\/j.intimp.2024.113544_b0050","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23073464","article-title":"Dysbiosis in Inflammatory Bowel Disease: Pathogenic Role and Potential Therapeutic Targets","volume":"23","author":"Santana","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.intimp.2024.113544_b0055","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1016\/j.cmet.2021.05.005","article-title":"Fecal microbiota transplantation in human metabolic diseases: From a murky past to a bright future?","volume":"33","author":"Hanssen","year":"2021","journal-title":"Cell Metab."},{"key":"10.1016\/j.intimp.2024.113544_b0060","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1053\/j.gastro.2020.09.056","article-title":"Inflammatory Bowel Diseases (IBD) and the MicrobiomeSearching the Crime Scene for Clues","volume":"160","author":"Lee","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1016\/j.intimp.2024.113544_b0065","unstructured":"The morbid anatomy of some of the most important parts of the human body - Digital Collections - National Library of Medicine, (n.d.). https:\/\/collections.nlm.nih.gov\/catalog\/nlm:nlmuid-2542005R-bk (accessed August 13, 2023)."},{"key":"10.1016\/j.intimp.2024.113544_b0070","first-page":"264","article-title":"Morbid appearances in the intestine of Miss Bankes","volume":"2","author":"Wilks","year":"1859","journal-title":"Med times Gazette"},{"key":"10.1016\/j.intimp.2024.113544_b0075","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1136\/bmj.290.6461.47","article-title":"MEDICAL HISTORY-INFLAMMATORY BOWEL-DISEASE","volume":"290","author":"Fielding","year":"1985","journal-title":"Br. Med. J."},{"key":"10.1016\/j.intimp.2024.113544_b0080","first-page":"201","article-title":"A new use of the useless appendix in the treatment of obstinate colitis","volume":"62","author":"Weir","year":"1902","journal-title":"NY Med J"},{"key":"10.1016\/j.intimp.2024.113544_b0085","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1001\/jama.1924.02660050018004","article-title":"Experimental studies on the etiology of chronic ulcerative colitis: Preliminary report","volume":"83","author":"Bargen","year":"1924","journal-title":"J. Am. Med. Assoc."},{"key":"10.1016\/j.intimp.2024.113544_b0090","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1001\/archinte.1925.00120180070007","article-title":"THE ETIOLOGY OF CHRONIC ULCERATIVE COLITIS: EXPERIMENTAL STUDIES WITH SUGGESTIONS FOR A MORE RATIONAL FORM OF TREATMENT","volume":"36","author":"Bargen","year":"1925","journal-title":"Arch. Intern. Med."},{"key":"10.1016\/j.intimp.2024.113544_b0095","doi-asserted-by":"crossref","first-page":"175","DOI":"10.3748\/wjg.v7.i2.175","article-title":"Historical origins of current IBD concepts","volume":"7","author":"Kirsner","year":"2001","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.intimp.2024.113544_b0100","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1097\/00004836-198806000-00012","article-title":"Historical aspects of inflammatory bowel disease","volume":"10","author":"Kirsner","year":"1988","journal-title":"J. Clin. Gastroenterol."},{"key":"10.1016\/j.intimp.2024.113544_b0105","first-page":"407","article-title":"Regional enteritis with special reference to its etiology and pathogenesis","volume":"88","author":"Tallroth","year":"1943","journal-title":"Acta Chir Scand"},{"key":"10.1016\/j.intimp.2024.113544_b0110","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S0025-6196(24)00526-3","article-title":"The effect of a hormone of the adrenal cortex (17-hydroxy-11-dehydrocorticosterone; compound E) and of pituitary adrenocorticotropic hormone on rheumatoid arthritis","volume":"24","author":"Hench","year":"1949","journal-title":"Proc Staff Meet Mayo Clin"},{"key":"10.1016\/j.intimp.2024.113544_b0115","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0016-5085(51)80211-7","article-title":"The effect of ACTH on nonspecific ulcerative colitis","volume":"17","author":"Rossmiller","year":"1951","journal-title":"Gastroenterology"},{"key":"10.1016\/j.intimp.2024.113544_b0120","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1136\/bmj.2.4884.375","article-title":"Cortisone in Ulcerative Colitis","volume":"2","author":"Truelove","year":"1954","journal-title":"Br Med J"},{"key":"10.1016\/j.intimp.2024.113544_b0125","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1136\/bmj.2.4947.1041","article-title":"Cortisone in ulcerative colitis; final report on a therapeutic trial","volume":"2","author":"Truelove","year":"1955","journal-title":"Br Med J"},{"key":"10.1016\/j.intimp.2024.113544_b0130","first-page":"102","article-title":"The production of an experimental ulcerative colitis in rabbits","volume":"70","author":"Elchlepp","year":"1957","journal-title":"Trans. Assoc. Am. Physicians"},{"key":"10.1016\/j.intimp.2024.113544_b0135","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/S0022-4804(63)80065-7","article-title":"The auer phenomenon in colon-sensitized mice: Histopathology of colonic lesions","volume":"3","author":"Callahan","year":"1963","journal-title":"J. Surg. Res."},{"key":"10.1016\/j.intimp.2024.113544_b0140","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1084\/jem.110.5.657","article-title":"Autoantibodies in human ulcerative colitis","volume":"110","author":"Broberger","year":"1959","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.intimp.2024.113544_b0145","unstructured":"E. Bregman, J. Kirsner, Colon antibodies in ulcerative colitis, in: MOSBY-Year Book INC 11830 Westline Industrial DR, ST LOUIS, MO 63146-3318, 1960: pp. 795\u2013795."},{"key":"10.1016\/j.intimp.2024.113544_b0150","first-page":"1129","article-title":"Sur la presence d\u2019anticorps anti-colon dans le serum de malades atteints de colite ulcereuse","volume":"28","author":"Bernier","year":"1960","journal-title":"Bull. Soc. M\u00e9d. H\u00f4p. Paris"},{"key":"10.1016\/j.intimp.2024.113544_b0155","unstructured":"J. Heremans, Les globulines s\u00e9riques du syst\u00e8me gamma: leur nature et leur pathologie, (1960)."},{"key":"10.1016\/j.intimp.2024.113544_b0160","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1084\/jem.121.1.101","article-title":"Characteristics of an immune system common to certain external secretions","volume":"121","author":"Tomasi","year":"1965","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.intimp.2024.113544_b0165","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/S0016-5085(19)31672-5","article-title":"Role of prostaglandins in ulcerative colitis: enhanced production during active disease and inhibition by sulfasalazine","volume":"75","author":"Sharon","year":"1978","journal-title":"Gastroenterology"},{"key":"10.1016\/j.intimp.2024.113544_b0170","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/S0016-5085(84)80015-3","article-title":"Enhanced synthesis of leukotriene B4 by colonic mucosa in inflammatory bowel disease","volume":"86","author":"Sharon","year":"1984","journal-title":"Gastroenterology"},{"key":"10.1016\/j.intimp.2024.113544_b0175","first-page":"55","article-title":"Metabolism of arachidonic acid in acetic acid colitis in rats","volume":"88","author":"Sharon","year":"1985","journal-title":"Similarity to Human Inflammatory Bowel Disease, Gastroenterology"},{"key":"10.1016\/j.intimp.2024.113544_b0180","doi-asserted-by":"crossref","first-page":"6S","DOI":"10.1007\/BF01538126","article-title":"Neutrophil-mediated mucosal injury: role of reactive oxygen metabolites","volume":"33","author":"Grisham","year":"1988","journal-title":"Dig. Dis. Sci."},{"key":"10.1016\/j.intimp.2024.113544_b0185","doi-asserted-by":"crossref","unstructured":"C.A. Dinarello, Interleukin-1 and interleukin-1 antagonism, (1991).","DOI":"10.1182\/blood.V77.8.1627.1627"},{"key":"10.1016\/j.intimp.2024.113544_b0190","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1152\/physrev.1960.40.3.580","article-title":"Pathogenesis of fever","volume":"40","author":"Atkins","year":"1960","journal-title":"Physiol Rev"},{"key":"10.1016\/j.intimp.2024.113544_b0195","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1136\/bmj.285.6334.20","article-title":"Intestinal permeability in children with Crohn\u2019s disease and coeliac disease","volume":"285","author":"Pearson","year":"1982","journal-title":"Br Med J (clin Res Ed)"},{"key":"10.1016\/j.intimp.2024.113544_b0200","first-page":"537","article-title":"A freeze fracture study of Crohn\u2019s disease of the terminal ileum: changes in epithelial tight junction organization","volume":"78","author":"Marin","year":"1983","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.intimp.2024.113544_b0205","first-page":"70","article-title":"Abnormal small intestinal permeability to sugars in patients with Crohn\u2019s disease of the terminal ileum and colon","volume":"27","author":"Ukabam","year":"1983","journal-title":"Digestion"},{"key":"10.1016\/j.intimp.2024.113544_b0210","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/0016-5085(83)90317-7","article-title":"Absorption of 51chromium-labeled ethylenediaminetetraacetate in inflammatory bowel disease","volume":"85","author":"Bjarnason","year":"1983","journal-title":"Gastroenterology"},{"key":"10.1016\/j.intimp.2024.113544_b0215","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1136\/gut.29.12.1621","volume":"29","author":"Hollander","year":"1988","journal-title":"Gut"},{"key":"10.1016\/j.intimp.2024.113544_b0220","first-page":"883","article-title":"Increased intestinal permeability in patients with Crohn\u2019s disease and their relatives","volume":"105","author":"Hollander","year":"1986","journal-title":"A Possible Etiologic Factor, Ann Intern Med"},{"key":"10.1016\/j.intimp.2024.113544_b0225","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/0016-5085(89)91499-6","article-title":"Intestinal permeability in patients with Crohn\u2019s disease and their healthy relatives","volume":"97","author":"Katz","year":"1989","journal-title":"Gastroenterology"},{"key":"10.1016\/j.intimp.2024.113544_b0230","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1007\/s11894-999-0023-5","article-title":"Intestinal permeability, leaky gut, and intestinal disorders","volume":"1","author":"Hollander","year":"1999","journal-title":"Curr Gastroenterol Rep"},{"key":"10.1016\/j.intimp.2024.113544_b0235","article-title":"The effects and cell barrier mechanism of main dietary nutrients on intestinal barrier","volume":"48","author":"Fan","year":"2022","journal-title":"Curr. Opin. Food Sci."},{"key":"10.1016\/j.intimp.2024.113544_b0240","article-title":"Enhancing intestinal barrier efficiency: A novel metabolic diseases therapy","volume":"10","author":"Zhang","year":"2023","journal-title":"Front. Nutr."},{"key":"10.1016\/j.intimp.2024.113544_b0245","doi-asserted-by":"crossref","first-page":"2652","DOI":"10.1056\/NEJMra2002697","article-title":"Pathophysiology of Inflammatory Bowel Diseases","volume":"383","author":"Chang","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.intimp.2024.113544_b0250","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2022.1065608","article-title":"New insights into bacterial mechanisms and potential intestinal epithelial cell therapeutic targets of inflammatory bowel disease","volume":"13","author":"Liang","year":"2022","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.intimp.2024.113544_b0255","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12967-018-1441-7","article-title":"Oral Escherichia coli expressing IL-35 meliorates experimental colitis in mice","volume":"16","author":"Zhang","year":"2018","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.intimp.2024.113544_b0260","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1016\/j.immuni.2019.03.017","article-title":"Cytokine Networks in the Pathophysiology of Inflammatory Bowel Disease","volume":"50","author":"Friedrich","year":"2019","journal-title":"Immunity"},{"key":"10.1016\/j.intimp.2024.113544_b0265","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1114348","article-title":"The intestine: A highly dynamic microenvironment for IgA plasma cells","volume":"14","author":"Pracht","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2024.113544_b0270","doi-asserted-by":"crossref","DOI":"10.1002\/eji.202350631","article-title":"Epithelial-immune cell crosstalk for intestinal barrier homeostasis","volume":"54","author":"Yao","year":"2024","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.intimp.2024.113544_b0275","doi-asserted-by":"crossref","unstructured":"G.W. Sewell, A. Kaser, Interleukin-23 in the Pathogenesis of Inflammatory Bowel Disease and Implications for Therapeutic Intervention, Journal of Crohn\u2019s and Colitis 16 (2022) ii3\u2013ii19. Doi: 10.1093\/ecco-jcc\/jjac034.","DOI":"10.1093\/ecco-jcc\/jjac034"},{"key":"10.1016\/j.intimp.2024.113544_b0280","doi-asserted-by":"crossref","first-page":"26","DOI":"10.5217\/ir.2018.16.1.26","article-title":"Immunological pathogenesis of inflammatory bowel disease","volume":"16","author":"Lee","year":"2018","journal-title":"Intest Res"},{"key":"10.1016\/j.intimp.2024.113544_b0285","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12967-019-02174-1","article-title":"Integrating omics for a better understanding of Inflammatory Bowel Disease: a step towards personalized medicine","volume":"17","author":"Kumar","year":"2019","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.intimp.2024.113544_b0290","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/j.1755-3768.1968.tb05926.x","article-title":"The Goblet Cell in General","volume":"46","author":"Chapter","year":"1968","journal-title":"Acta Ophthalmol."},{"key":"10.1016\/j.intimp.2024.113544_b0295","first-page":"202","article-title":"Mucus secretion from colonic goblet cells is regulated by autophagy and ER stress, Nature Reviews","volume":"20","author":"Hindson","year":"2023","journal-title":"Gastroenterology & Hepatology"},{"key":"10.1016\/j.intimp.2024.113544_b0300","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24021526","article-title":"Pathophysiology of Inflammatory Bowel Disease: Innate Immune System","volume":"24","author":"Saez","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.intimp.2024.113544_b0305","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/s41586-019-0992-y","article-title":"Colonic epithelial cell diversity in health and inflammatory bowel disease","volume":"567","author":"Parikh","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.intimp.2024.113544_b0310","first-page":"219","article-title":"Chronic inflammation in ulcerative colitis causes long-term changes in goblet cell function, Cellular and Molecular","volume":"13","author":"Singh","year":"2022","journal-title":"Gastroenterology and Hepatology"},{"key":"10.1016\/j.intimp.2024.113544_b0315","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2022.848344","article-title":"The role and function of mucins and its relationship to inflammatory bowel disease","volume":"9","author":"Kang","year":"2022","journal-title":"Front. Med."},{"key":"10.1016\/j.intimp.2024.113544_b0320","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1002\/ibd.21592","article-title":"Colonic gene expression patterns of mucin Muc2 knockout mice reveal various phases in colitis development","volume":"17","author":"Lu","year":"2011","journal-title":"Inflamm. Bowel Dis."},{"key":"10.1016\/j.intimp.2024.113544_b0325","doi-asserted-by":"crossref","first-page":"21135","DOI":"10.1038\/s41598-020-78141-4","article-title":"Mucin-2 knockout is a model of intercellular junction defects, mitochondrial damage and ATP depletion in the intestinal epithelium","volume":"10","author":"Borisova","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.intimp.2024.113544_b0330","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.3390\/jcm10091935","article-title":"The relationship between mucins and ulcerative colitis: a systematic review","volume":"10","author":"Bankole","year":"2021","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.intimp.2024.113544_b0335","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1136\/gut.10.10.804","article-title":"The Paneth cell in disease","volume":"10","author":"Lewin","year":"1969","journal-title":"Gut"},{"key":"10.1016\/j.intimp.2024.113544_b0340","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/0005-2744(67)90136-2","article-title":"Localization of lysozyme activity in a Paneth cell granule fraction","volume":"139","author":"Deckx","year":"1967","journal-title":"Biochimica et Biophysica Acta (BBA)-Enzymology"},{"key":"10.1016\/j.intimp.2024.113544_b0345","doi-asserted-by":"crossref","DOI":"10.1111\/cpr.12958","article-title":"The roles and functions of Paneth cells in Crohn\u2019s disease: A critical review","volume":"54","author":"Yang","year":"2021","journal-title":"Cell Prolif."},{"key":"10.1016\/j.intimp.2024.113544_b0350","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1136\/gutjnl-2019-319514","article-title":"Mitochondrial impairment drives intestinal stem cell transition into dysfunctional Paneth cells predicting Crohn\u2019s disease recurrence","volume":"69","author":"Khaloian","year":"2020","journal-title":"Gut"},{"key":"10.1016\/j.intimp.2024.113544_b0355","doi-asserted-by":"crossref","unstructured":"S. Khaloian Sarnaghi, Mitochondrial impairment drives intestinal stem cell transition towards dysfunctional Paneth cells predicting Crohn\u2019s disease recurrence, (2021).","DOI":"10.1136\/gutjnl-2019-319514"},{"key":"10.1016\/j.intimp.2024.113544_b0360","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.crohns.2010.05.010","article-title":"Paneth\u2019s disease","volume":"4","author":"Wehkamp","year":"2010","journal-title":"Journal of Crohn\u2019s and Colitis"},{"key":"10.1016\/j.intimp.2024.113544_b0365","doi-asserted-by":"crossref","first-page":"646","DOI":"10.3389\/fimmu.2020.00646","article-title":"An update review on the Paneth cell as key to ileal Crohn\u2019s disease","volume":"11","author":"Wehkamp","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2024.113544_b0370","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1053\/j.gastro.2019.07.031","article-title":"Interferon lambda promotes paneth cell death via STAT1 signaling in mice and is increased in inflamed ileal tissues of patients with Crohn\u2019s disease","volume":"157","author":"G\u00fcnther","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1016\/j.intimp.2024.113544_b0375","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12967-019-2070-5","article-title":"Vitamin D deficiency associated with Crohn\u2019s disease and ulcerative colitis: a meta-analysis of 55 observational studies","volume":"17","author":"Li","year":"2019","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.intimp.2024.113544_b0380","doi-asserted-by":"crossref","first-page":"693","DOI":"10.3389\/fimmu.2018.00693","article-title":"Impact of paneth cell autophagy on inflammatory bowel disease","volume":"9","author":"Wang","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2024.113544_b0385","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.jaci.2009.05.038","article-title":"Intestinal barrier function: molecular regulation and disease pathogenesis","volume":"124","author":"Groschwitz","year":"2009","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.intimp.2024.113544_b0390","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2021.643607","article-title":"Angiocrine regulation of epithelial barrier integrity in inflammatory bowel disease","volume":"8","author":"St\u00fcrzl","year":"2021","journal-title":"Front. Med."},{"key":"10.1016\/j.intimp.2024.113544_b0395","doi-asserted-by":"crossref","first-page":"3117","DOI":"10.3748\/wjg.v22.i11.3117","article-title":"Tight junctions in inflammatory bowel diseases and inflammatory bowel disease associated colorectal cancer","volume":"22","author":"Landy","year":"2016","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.intimp.2024.113544_b0400","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1093\/ecco-jcc\/jjac168","article-title":"Long-Term Use of Proton Pump Inhibitors Disrupts Intestinal Tight Junction Barrier and Exaggerates Experimental Colitis","volume":"17","author":"Nighot","year":"2023","journal-title":"Journal of Crohn\u2019s and Colitis"},{"key":"10.1016\/j.intimp.2024.113544_b0405","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1093\/ecco-jcc\/jjab044","article-title":"Overexpression of Vitamin D Receptor in Intestinal Epithelia Protects Against Colitis via Upregulating Tight Junction Protein Claudin 15","volume":"15","author":"Chatterjee","year":"2021","journal-title":"Journal of Crohn\u2019s and Colitis"},{"key":"10.1016\/j.intimp.2024.113544_b0410","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1111\/j.1365-2249.1990.tb03334.x","article-title":"Tumour necrosis factor-alpha and interferon-gamma production measured at the single cell level in normal and inflamed human intestine","volume":"81","author":"MacDonald","year":"1990","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.intimp.2024.113544_b0415","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1016\/0161-5890(93)90106-L","article-title":"Construction and initial characterization of a mouse-human chimeric anti-TNF antibody","volume":"30","author":"Knight","year":"1993","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.intimp.2024.113544_b0420","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1016\/S0140-6736(94)90628-9","article-title":"Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor \u03b1 (cA2) versus placebo in rheumatoid arthritis","volume":"344","author":"Elliott","year":"1994","journal-title":"Lancet"},{"key":"10.1016\/j.intimp.2024.113544_b0425","unstructured":"Centocor, Inc., A Placebo-Controlled, Dose-Ranging Study Followed by a Placebo-Controlled, Repeated-Dose Extension of Anti-TNF Chimeric Monoclonal Antibody (cA2) in the Treatment of Patients With Active Crohn\u2019s Disease, clinicaltrials.gov, 2014. https:\/\/clinicaltrials.gov\/study\/NCT00269854 (accessed August 16, 2023)."},{"key":"10.1016\/j.intimp.2024.113544_b0430","first-page":"139","article-title":"Remicade\u00ae (infliximab): 20 years of contributions to science and medicine","volume":"13","author":"Melsheimer","year":"2019","journal-title":"Biologics"},{"key":"10.1016\/j.intimp.2024.113544_b0435","unstructured":"FDA Approves TYSABRI(R) for the Treatment of Moderate-to-Severe Crohn\u2019s Disease | Biogen, (n.d.). https:\/\/investors.biogen.com\/news-releases\/news-release-details\/fda-approves-tysabrir-treatment-moderate-severe-crohns-disease (accessed August 20, 2023)."},{"key":"10.1016\/j.intimp.2024.113544_b0440","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.3174\/ajnr.A2226","article-title":"Natalizumab (Tysabri)","volume":"31","author":"Selewski","year":"2010","journal-title":"AJNR Am J Neuroradiol"},{"key":"10.1016\/j.intimp.2024.113544_b0445","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.612830","article-title":"Vedolizumab: Potential Mechanisms of Action for Reducing Pathological Inflammation in Inflammatory Bowel Diseases","volume":"9","author":"Luzentales-Simpson","year":"2021","journal-title":"Front Cell Dev Biol"},{"key":"10.1016\/j.intimp.2024.113544_b0450","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2019.00039","article-title":"Cellular Mechanisms of Etrolizumab Treatment in Inflammatory Bowel Disease","volume":"10","author":"Lichnog","year":"2019","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.intimp.2024.113544_b0455","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1093\/ecco-jcc\/jjx079","article-title":"Positioning Ustekinumab in Crohn\u2019s Disease: From Clinical Evidence to Clinical Practice","volume":"11","author":"Danese","year":"2017","journal-title":"Journal of Crohn\u2019s and Colitis"},{"key":"10.1016\/j.intimp.2024.113544_b0460","unstructured":"I.S. Padda, R. Bhatt, M. Parmar, Tofacitinib, in: StatPearls, StatPearls Publishing, Treasure Island (FL), 2023. http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK572148\/ (accessed August 20, 2023)."},{"key":"10.1016\/j.intimp.2024.113544_b0465","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2022.108517","article-title":"Tofacitinib for extraintestinal manifestations of inflammatory bowel disease: A literature review","volume":"105","author":"Wang","year":"2022","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.intimp.2024.113544_b0470","unstructured":"Bristol Myers Squibb - U.S. Food and Drug Administration Approves Bristol Myers Squibb\u2019s Zeposia\u00ae (ozanimod), an Oral Treatment for Adults with Moderately to Severely Active Ulcerative Colitis, (n.d.). https:\/\/news.bms.com\/news\/details\/2021\/U.S.-Food-and-Drug-Administration-Approves-Bristol-Myers-Squibbs-Zeposia-ozanimod-an-Oral-Treatment-for-Adults-with-Moderately-to-Severely-Active-Ulcerative-Colitis1\/default.aspx (accessed August 20, 2023) .[95] SKYRIZI\u00ae (risankizumab-rzaa) Receives FDA Approval as the First and Only Specific Interleukin-23 (IL-23) to Treat Moderately to Severely Active Crohn\u2019s Disease in Adults | AbbVie News Center, (n.d.). https:\/\/news.abbvie.com\/news\/press-releases\/skyrizi-risankizumab-rzaa-receives-fda-approval-as-first-and-only-specific-interleukin-23-il-23-to-treat-moderately-to-severely-active-crohns-disease-in-adults.htm (accessed August 20, 2023)."},{"key":"10.1016\/j.intimp.2024.113544_b0475","unstructured":"SKYRIZI\u00ae (risankizumab-rzaa) Receives FDA Approval as the First and Only Specific Interleukin-23 (IL-23) to Treat Moderately to Severely Active Crohn\u2019s Disease in Adults | AbbVie News Center, (n.d.). https:\/\/news.abbvie.com\/news\/press-releases\/skyrizi-risankizumab-rzaa-receives-fda-approval-as-first-and-only-specific-interleukin-23-il-23-to-treat-moderately-to-severely-active-crohns-disease-in-adults.htm (accessed August 20, 2023)."},{"key":"10.1016\/j.intimp.2024.113544_b0555","doi-asserted-by":"crossref","DOI":"10.1177\/2040622319838443","article-title":"Infliximab in inflammatory bowel disease","volume":"10","author":"Papamichael","year":"2019","journal-title":"Therapeutic Advances in Chronic Disease"},{"key":"10.1016\/j.intimp.2024.113544_b0560","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1186\/s12967-024-05058-1","article-title":"Predictive biomarkers for anti-TNF alpha therapy in IBD patients","volume":"22","author":"Kumar","year":"2024","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.intimp.2024.113544_b0565","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1093\/ecco-jcc\/jjz018","article-title":"Proactive Therapeutic Drug Monitoring of Adalimumab Is Associated With Better Long-term Outcomes Compared With Standard of Care in Patients With Inflammatory Bowel Disease","volume":"13","author":"Papamichael","year":"2019","journal-title":"Journal of Crohn\u2019s and Colitis"},{"key":"10.1016\/j.intimp.2024.113544_b0570","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1093\/ibd\/izz199","article-title":"Identification of Target Golimumab Levels in Maintenance Therapy of Crohn\u2019s Disease and Ulcerative Colitis Associated With Mucosal Healing","volume":"26","author":"Boland","year":"2020","journal-title":"Inflamm. Bowel Dis."},{"key":"10.1016\/j.intimp.2024.113544_b0575","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1177\/2050640620974308","article-title":"Two\u2010year effectiveness and safety of golimumab in ulcerative colitis: An IG\u2010IBD study","volume":"9","author":"Pugliese","year":"2021","journal-title":"UEG Journal"},{"key":"10.1016\/j.intimp.2024.113544_b0580","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1093\/ecco-jcc\/jjz195","article-title":"Predictors of Primary Response to Biologic Treatment [Anti-TNF, Vedolizumab, and Ustekinumab] in Patients With Inflammatory Bowel Disease: From Basic Science to Clinical Practice","volume":"14","author":"Gisbert","year":"2020","journal-title":"Journal of Crohn\u2019s and Colitis"},{"key":"10.1016\/j.intimp.2024.113544_b0585","article-title":"Oral delivery of biologics in inflammatory bowel disease treatment","volume":"9","author":"Zhang","year":"2021","journal-title":"Front. Bioeng. Biotechnol."},{"key":"10.1016\/j.intimp.2024.113544_b0590","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fmed.2021.640813","article-title":"How to optimize treatment with ustekinumab in inflammatory bowel disease: lessons learned from clinical trials and real-world data","volume":"8","author":"Guti\u00e9rrez","year":"2021","journal-title":"Front. Med."},{"key":"10.1016\/j.intimp.2024.113544_b0595","doi-asserted-by":"crossref","first-page":"i355","DOI":"10.1093\/ecco-jcc\/jjab232.467","article-title":"P340 Risankizumab in Inflammatory Bowel Disease: Real World Experience from a Pre-Approval Access Program","volume":"16","author":"Dawson","year":"2022","journal-title":"Journal of Crohn\u2019s and Colitis"},{"key":"10.1016\/j.intimp.2024.113544_b0600","doi-asserted-by":"crossref","first-page":"S404","DOI":"10.1093\/ecco-jcc\/jjab076.519","article-title":"P395 Impact of mirikizumab therapy on histologic measures of intestinal inflammation in a Phase 2 study of patients with moderately to severely active Crohn\u2019s disease","volume":"15","author":"Pai","year":"2021","journal-title":"Journal of Crohn\u2019s and Colitis"},{"key":"10.1016\/j.intimp.2024.113544_b0605","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1053\/j.gastro.2021.10.050","article-title":"Efficacy and Safety of Mirikizumab in a Randomized Phase 2 Study of Patients With Crohn\u2019s Disease","volume":"162","author":"Sands","year":"2022","journal-title":"Gastroenterology"},{"key":"10.1016\/j.intimp.2024.113544_b0615","doi-asserted-by":"crossref","DOI":"10.1177\/1756284819853208","article-title":"New biologics and small molecules in inflammatory bowel disease: an update","volume":"12","author":"Sabino","year":"2019","journal-title":"Therap Adv Gastroenterol"},{"key":"10.1016\/j.intimp.2024.113544_b0620","doi-asserted-by":"crossref","unstructured":"B.E. Sands, B.G. Feagan, W.J. Sandborn, N. Shipitofsky, M. Marko, S. Sheng, J. Johanns, M. Germinaro, M. Vetter, J. Pan\u00e9s, VEGA, OP36 Efficacy and safety of combination induction therapy with guselkumab and golimumab in participants with moderately-to-severely active Ulcerative Colitis: Results through week 12 of a phase 2a randomized, double-blind, active-controlled, parallel-group, multicenter, proof-of-concept study, Journal of Crohn\u2019s and Colitis 16 (2022) i042\u2013i043. Doi: 10.1093\/ecco-jcc\/jjab232.035.","DOI":"10.1093\/ecco-jcc\/jjab232.035"},{"key":"10.1016\/j.intimp.2024.113544_b0625","doi-asserted-by":"crossref","unstructured":"A. Dignass, D. Rubin, B. Bressler, K.H. Huang, N. Shipitofsky, M. Germinaro, H. Zhang, J. Johanns, B. Feagan, W. Sandborn, B. Sands, T. Hisamatsu, G. Lichtenstein, J. Panes, J. Allegretti, QUASAR Investigators, OP23 The efficacy and safety of guselkumab induction therapy in patients with moderately to severely active Ulcerative Colitis: Phase 2b QUASAR Study results through week 12, Journal of Crohn\u2019s and Colitis 16 (2022) i025\u2013i026. Doi: 10.1093\/ecco-jcc\/jjab232.022.","DOI":"10.1093\/ecco-jcc\/jjab232.022"},{"key":"10.1016\/j.intimp.2024.113544_b0630","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1136\/gutjnl-2017-314562","article-title":"Rupert W Leong, Gail M Comer, Fabio Cataldi, Anindita Banerjee, Mary K Maguire, Cheryl Li, Natalie Rath, Jean Beebe, Stefan Schreiber, Randomised trial and open-label extension study of an anti-interleukin-6 antibody in Crohn\u2019s disease (ANDANTE I and II)","volume":"68","author":"Danese","year":"2019","journal-title":"Gut"},{"key":"10.1016\/j.intimp.2024.113544_b0635","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1111\/apt.16060","article-title":"Long-term safety of vedolizumab for inflammatory bowel disease","volume":"52","author":"Loftus","year":"2020","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.intimp.2024.113544_b0640","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1111\/apt.12639","article-title":"Review article: anti-adhesion therapies for inflammatory bowel disease","volume":"39","author":"Lobat\u00f3n","year":"2014","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.intimp.2024.113544_b0645","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1053\/j.gastro.2007.03.024","article-title":"Natalizumab for the Treatment of Active Crohn\u2019s Disease: Results of the ENCORE Trial","volume":"132","author":"Targan","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.intimp.2024.113544_b0650","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1016\/S2468-1253(22)00022-X","article-title":"AJM300 (carotegrast methyl), an oral antagonist of \u03b14-integrin, as induction therapy for patients with moderately active ulcerative colitis: a multicentre, randomised, double-blind, placebo-controlled, phase 3 study","volume":"7","author":"Matsuoka","year":"2022","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"10.1016\/j.intimp.2024.113544_b0655","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1007\/s40265-022-01732-0","article-title":"Carotegrast methyl: first approval","volume":"82","author":"Dhillon","year":"2022","journal-title":"Drugs"},{"key":"10.1016\/j.intimp.2024.113544_b0610","doi-asserted-by":"crossref","first-page":"8242","DOI":"10.3748\/wjg.v27.i48.8242","article-title":"Emerging therapeutic options in inflammatory bowel disease","volume":"27","author":"Yamamoto-Furusho","year":"2021","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.intimp.2024.113544_b0660","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/S2468-1253(21)00369-1","article-title":"Etrolizumab for ulcerative colitis: beyond what meets the eye","volume":"7","author":"Agrawal","year":"2022","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"10.1016\/j.intimp.2024.113544_b0665","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1053\/j.gastro.2018.11.035","article-title":"Efficacy and Safety of Abrilumab in a Randomized, Placebo-Controlled Trial for Moderate-to-Severe Ulcerative Colitis","volume":"156","author":"Sandborn","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1016\/j.intimp.2024.113544_b0670","doi-asserted-by":"crossref","first-page":"400","DOI":"10.3389\/fphar.2017.00400","article-title":"Frontiers in drug research and development for inflammatory bowel disease","volume":"8","author":"Curr\u00f2","year":"2017","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.intimp.2024.113544_b0675","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1080\/13543784.2021.1974396","article-title":"Anti-integrin drugs in clinical trials for inflammatory bowel disease (IBD): insights into promising agents","volume":"30","author":"Solitano","year":"2021","journal-title":"Expert Opin. Invest. Drugs"},{"key":"10.1016\/j.intimp.2024.113544_b0680","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1053\/j.gastro.2021.08.045","article-title":"PTG-100, an Oral \u03b14\u03b27 Antagonist Peptide: Preclinical Development and Phase 1 and 2a Studies in Ulcerative Colitis","volume":"161","author":"Sandborn","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1016\/j.intimp.2024.113544_b0685","doi-asserted-by":"crossref","unstructured":"L.L. Schulze, E. Becker, M. Dedden, L.-J. Liu, C. van Passen, M. Mohamed-Abdou, T.M. M\u00fcller, M. Wiendl, K.A.-M. Ullrich, I. Atreya, M. Leppkes, A.B. Ekici, P. Kirchner, M. St\u00fcrzl, D. Sexton, D. Palliser, R. Atreya, B. Siegmund, TRR241 IBDome consortium, M.F. Neurath, S. Zundler, Differential Effects of Ontamalimab Versus Vedolizumab on Immune Cell Trafficking in Intestinal Inflammation and Inflammatory Bowel Disease, Journal of Crohn\u2019s and Colitis (2023) jjad088. Doi: 10.1093\/ecco-jcc\/jjad088.","DOI":"10.1093\/ecco-jcc\/jjad088"},{"key":"10.1016\/j.intimp.2024.113544_b0690","first-page":"1688","article-title":"Lisa Lou Schulze","volume":"68","author":"Zundler","year":"2019","journal-title":"Markus F Neurath, Immune Cell Trafficking and Retention in Inflammatory Bowel Disease: Mechanistic Insights and Therapeutic Advances, Gut"},{"key":"10.1016\/j.intimp.2024.113544_b0695","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1093\/ecco-jcc\/jjab023","article-title":"Long-term Safety and Efficacy of the Anti-MAdCAM-1 Monoclonal Antibody Ontamalimab [SHP647] for the Treatment of Ulcerative Colitis: The Open-label Study TURANDOT II","volume":"15","author":"Reinisch","year":"2021","journal-title":"Journal of Crohn\u2019s and Colitis"},{"key":"10.1016\/j.intimp.2024.113544_b0700","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1093\/ecco-jcc\/jjy217","article-title":"Molecular Profiling of Ulcerative Colitis Subjects from the TURANDOT Trial Reveals Novel Pharmacodynamic\/Efficacy Biomarkers","volume":"13","author":"Zhou","year":"2019","journal-title":"Journal of Crohn\u2019s and Colitis"},{"key":"10.1016\/j.intimp.2024.113544_b0705","doi-asserted-by":"crossref","unstructured":"William J Sandborn, Scott D Lee, Dino Tarabar, Edouard Louis, Maria Klopocka, Jochen Klaus, Walter Reinisch, Xavier H\u00e9buterne, Dong-Il Park, Stefan Schreiber, Satyaprakash Nayak, Alaa Ahmad, Anindita Banerjee, Lisa S Brown, Fabio Cataldi, Kenneth J Gorelick, John B Cheng, Mina Hassan-Zahraee, Robert Clare, Geert R D\u2019Haens, Phase II evaluation of anti-MAdCAM antibody PF-00547659 in the treatment of Crohn\u2019s disease: report of the OPERA study, Gut 67 (2018) 1824. Doi: 10.1136\/gutjnl-2016-313457.","DOI":"10.1136\/gutjnl-2016-313457"},{"key":"10.1016\/j.intimp.2024.113544_b0710","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S0140-6736(17)30930-3","article-title":"Anti-MAdCAM antibody (PF-00547659) for ulcerative colitis (TURANDOT): a phase 2, randomised, double-blind, placebo-controlled trial","volume":"390","author":"Vermeire","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.intimp.2024.113544_b0715","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1080\/13543784.2018.1494722","article-title":"PF-00547659 for the treatment of Crohn\u2019s disease and ulcerative colitis","volume":"27","author":"Allocca","year":"2018","journal-title":"Expert Opin. Invest. Drugs"},{"key":"10.1016\/j.intimp.2024.113544_b0720","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/S2468-1253(20)30188-6","article-title":"Ozanimod induction therapy for patients with moderate to severe Crohn\u2019s disease: a single-arm, phase 2, prospective observer-blinded endpoint study","volume":"5","author":"Feagan","year":"2020","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"10.1016\/j.intimp.2024.113544_b0725","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1093\/ecco-jcc\/jjab012","article-title":"Long-Term Efficacy and Safety of Ozanimod in Moderately to Severely Active Ulcerative Colitis: Results From the Open-Label Extension of the Randomized, Phase 2 TOUCHSTONE Study","volume":"15","author":"Sandborn","year":"2021","journal-title":"Journal of Crohn\u2019s and Colitis"},{"key":"10.1016\/j.intimp.2024.113544_b0730","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1007\/s40265-022-01762-8","article-title":"Ozanimod: a review in ulcerative colitis","volume":"82","author":"Paik","year":"2022","journal-title":"Drugs"},{"key":"10.1016\/j.intimp.2024.113544_b0735","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1056\/NEJMoa2033617","article-title":"Ozanimod as Induction and Maintenance Therapy for Ulcerative Colitis","volume":"385","author":"Sandborn","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.intimp.2024.113544_b0740","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1007\/s40265-020-01319-7","article-title":"Ozanimod: First Approval","volume":"80","author":"Lamb","year":"2020","journal-title":"Drugs"},{"key":"10.1016\/j.intimp.2024.113544_b0745","doi-asserted-by":"crossref","unstructured":"G. D\u2019Haens, S. Danese, M. Davies, M. Watanabe, T. Hibi, A phase II, Multicentre, Randomised, Double-Blind, Placebo-controlled Study to Evaluate Safety, Tolerability, and Efficacy of Amiselimod in Patients with Moderate to Severe Active Crohn\u2019s Disease, Journal of Crohn\u2019s and Colitis 16 (2022) 746\u2013756. Doi: 10.1093\/ecco-jcc\/jjab201.","DOI":"10.1093\/ecco-jcc\/jjab201"},{"key":"10.1016\/j.intimp.2024.113544_b0750","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1053\/j.gastro.2019.11.042","article-title":"P095 Amiselimod safety profile for Crohn\u2019s disease, stratified by previous treatment with anti-TNF agents","volume":"158","author":"D\u2019Haens","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.intimp.2024.113544_b0755","doi-asserted-by":"crossref","unstructured":"G. D\u2019Haens, S. Danese, M. Davies, M. Watanabe, T. Hibi, DOP48 Amiselimod, a selective S1P receptor modulator in Crohn\u2019s disease patients: a proof-of-concept study, Journal of Crohn\u2019s and Colitis 13 (2019) S055\u2013S056. Doi: 10.1093\/ecco-jcc\/jjy222.082.","DOI":"10.1093\/ecco-jcc\/jjy222.082"},{"key":"10.1016\/j.intimp.2024.113544_b0760","doi-asserted-by":"crossref","first-page":"212","DOI":"10.3389\/fphar.2019.00212","article-title":"Targeting cytokine signaling and lymphocyte traffic via small molecules in inflammatory bowel disease: JAK inhibitors and S1PR agonists","volume":"10","author":"P\u00e9rez-Jeldres","year":"2019","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.intimp.2024.113544_b0765","doi-asserted-by":"crossref","unstructured":"Geert D\u2019Haens, William J Sandborn, Jean Frederic Colombel, Paul Rutgeerts, Kurt Brown, Hadas Barkay, Anat Sakov, Asi Haviv, Brian G Feagan, A phase II study of laquinimod in Crohn\u2019s disease, Gut 64 (2015) 1227. Doi: 10.1136\/gutjnl-2014-307118.","DOI":"10.1136\/gutjnl-2014-307118"},{"key":"10.1016\/j.intimp.2024.113544_b0770","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1136\/gutjnl-2019-318448","article-title":"JAK selectivity for inflammatory bowel disease treatment: does it clinically matter?","volume":"68","author":"Danese","year":"2019","journal-title":"Gut"},{"key":"10.1016\/j.intimp.2024.113544_b0775","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s40265-023-01840-5","article-title":"Safety of Janus Kinase Inhibitors in Inflammatory Bowel Diseases","volume":"83","author":"N\u00fa\u00f1ez","year":"2023","journal-title":"Drugs"},{"key":"10.1016\/j.intimp.2024.113544_b0780","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2023.111229","article-title":"Effectiveness and safety of upadacitinib for inflammatory bowel disease: A systematic review and meta-analysis of RCT and real-world observational studies","volume":"126","author":"Zheng","year":"2024","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.intimp.2024.113544_b0785","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1007\/s40265-022-01796-y","article-title":"Deucravacitinib: first approval","volume":"82","author":"Hoy","year":"2022","journal-title":"Drugs"},{"key":"10.1016\/j.intimp.2024.113544_b0790","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1093\/ecco-jcc\/jjx003","article-title":"The Future of Janus Kinase Inhibitors in Inflammatory Bowel Disease","volume":"11","author":"De Vries","year":"2017","journal-title":"Journal of Crohn\u2019s and Colitis"},{"key":"10.1016\/j.intimp.2024.113544_b0795","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1093\/ecco-jcc\/jjaa049","article-title":"Development of Gut-Selective Pan-Janus Kinase Inhibitor TD-1473 for Ulcerative Colitis: A Translational Medicine Programme","volume":"14","author":"Sandborn","year":"2020","journal-title":"Journal of Crohn\u2019s and Colitis"},{"key":"10.1016\/j.intimp.2024.113544_b0800","doi-asserted-by":"crossref","unstructured":"C. Harris, J.R.F. Cummings, JAK1 inhibition and inflammatory bowel disease, Rheumatology 60 (2021) ii45\u2013ii51. Doi: 10.1093\/rheumatology\/keaa896.","DOI":"10.1093\/rheumatology\/keaa896"},{"key":"10.1016\/j.intimp.2024.113544_b0805","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1021\/acschembio.9b00188","article-title":"PF-06651600, a Dual JAK3\/TEC Family Kinase Inhibitor","volume":"14","author":"Xu","year":"2019","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.intimp.2024.113544_b0810","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1093\/ecco-jcc\/jjy085","article-title":"Peficitinib-UC Study Group, Peficitinib, an Oral Janus Kinase Inhibitor, in Moderate-to-severe Ulcerative Colitis: Results From a Randomised, Phase 2 Study","volume":"12","author":"Sands","year":"2018","journal-title":"Journal of Crohn\u2019s and Colitis"},{"key":"10.1016\/j.intimp.2024.113544_b0815","first-page":"1063","article-title":"Cobitolimod for moderate-to-severe, left-sided ulcerative colitis (CONDUCT): a phase 2b randomised, double-blind, placebo-controlled, dose-ranging induction trial, The Lancet","volume":"5","author":"Atreya","year":"2020","journal-title":"Gastroenterology & Hepatology"},{"key":"10.1016\/j.intimp.2024.113544_b0820","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1093\/ecco-jcc\/jjz170","article-title":"The TLR9 Agonist Cobitolimod Induces IL10-Producing Wound Healing Macrophages and Regulatory T Cells in Ulcerative Colitis","volume":"14","author":"Schmitt","year":"2020","journal-title":"Journal of Crohn\u2019s and Colitis"},{"key":"10.1016\/j.intimp.2024.113544_b0825","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines11030747","article-title":"Exploring the Pipeline of Novel Therapies for Inflammatory Bowel Disease; State of the Art Review","volume":"11","author":"Zurba","year":"2023","journal-title":"Biomedicines"},{"key":"10.1016\/j.intimp.2024.113544_b0830","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1007\/s40265-022-01801-4","article-title":"Spesolimab: first approval","volume":"82","author":"Blair","year":"2022","journal-title":"Drugs"},{"key":"10.1016\/j.intimp.2024.113544_b0835","doi-asserted-by":"crossref","first-page":"2526","DOI":"10.1016\/j.cgh.2019.12.032","article-title":"Effects of Apremilast, an Oral Inhibitor of Phosphodiesterase 4, in a Randomized Trial of Patients With Active Ulcerative Colitis","volume":"18","author":"Danese","year":"2020","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.intimp.2024.113544_b0840","doi-asserted-by":"crossref","first-page":"10113","DOI":"10.1021\/acs.jmedchem.6b00412","article-title":"An N,N-Bis(benzimidazolylpicolinoyl)piperazine (BT-11): A Novel Lanthionine Synthetase C-Like 2-Based Therapeutic for Inflammatory Bowel Disease","volume":"59","author":"Carbo","year":"2016","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.intimp.2024.113544_b0845","first-page":"643","article-title":"The Safety, Tolerability, and Pharmacokinetics Profile of BT-11, an Oral, Gut-Restricted Lanthionine Synthetase C-Like 2 Agonist Investigational New Drug for Inflammatory Bowel Disease: A Randomized, Double-Blind, Placebo-Controlled Phase I Clinical Trial","volume":"26","author":"Leber","year":"2020","journal-title":"Inflamm. Bowel Dis."},{"key":"10.1016\/j.intimp.2024.113544_b0520","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1016\/S2468-1253(22)00233-3","article-title":"ABX464 (obefazimod) for moderate-to-severe, active ulcerative colitis: a phase 2b, double-blind, randomised, placebo-controlled induction trial and 48 week, open-label extension","volume":"7","author":"Vermeire","year":"2022","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"10.1016\/j.intimp.2024.113544_b0850","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1016\/j.drudis.2020.12.019","article-title":"Specific and selective induction of miR-124 in immune cells by the quinoline ABX464: a transformative therapy for inflammatory diseases","volume":"26","author":"Tazi","year":"2021","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.intimp.2024.113544_b0855","doi-asserted-by":"crossref","first-page":"2595","DOI":"10.1053\/j.gastro.2021.02.054","article-title":"Induction and long-term follow-up with ABX464 for moderate-to-severe ulcerative colitis: results of phase IIA trial","volume":"160","author":"Vermeire","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1016\/j.intimp.2024.113544_b0480","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1080\/14740338.2022.2103536","article-title":"Safety and tolerability of spesolimab in patients with ulcerative colitis","volume":"22","author":"Ferrante","year":"2023","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.intimp.2024.113544_b0485","doi-asserted-by":"crossref","first-page":"314","DOI":"10.3389\/fphar.2019.00314","article-title":"Oligonucleotides\u2014a novel promising therapeutic option for IBD","volume":"10","author":"Scarozza","year":"2019","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.intimp.2024.113544_b0490","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1007\/s40265-017-0709-1","article-title":"Apremilast: A Review in Psoriasis and Psoriatic Arthritis","volume":"77","author":"Keating","year":"2017","journal-title":"Drugs"},{"key":"10.1016\/j.intimp.2024.113544_b0495","unstructured":"I.S. Padda, R. Bhatt, M. Parmar, Apremilast, in: StatPearls, StatPearls Publishing, Treasure Island (FL), 2024. http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK572078\/ (accessed February 4, 2024)."},{"key":"10.1016\/j.intimp.2024.113544_b0500","doi-asserted-by":"crossref","DOI":"10.3390\/ijms18061276","article-title":"PDE4 Inhibition and Inflammatory Bowel Disease: A Novel Therapeutic Avenue","volume":"18","author":"Spadaccini","year":"2017","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.intimp.2024.113544_b0505","first-page":"118","article-title":"S1076\u2003Efficacy and Safety of Omilancor in a Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial of Patients With Crohn\u2019s Disease","author":"Leber","year":"2023","journal-title":"Official Journal of the American College of Gastroenterology | ACG"},{"key":"10.1016\/j.intimp.2024.113544_b0510","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1093\/ecco-jcc\/jjad067","article-title":"Obefazimod: A First-in-class Drug for the Treatment of Ulcerative Colitis","volume":"17","author":"Vermeire","year":"2023","journal-title":"Journal of Crohn\u2019s and Colitis"},{"key":"10.1016\/j.intimp.2024.113544_b0515","doi-asserted-by":"crossref","first-page":"i169","DOI":"10.1093\/ecco-jcc\/jjac190.0131","article-title":"P001 Obefazimod upregulates miR-124 and downregulates the expression of some cytokines in blood and rectal biopsies of patients with moderate-to-severe ulcerative colitis","volume":"17","author":"Santo","year":"2023","journal-title":"Journal of Crohn\u2019s and Colitis"},{"key":"10.1016\/j.intimp.2024.113544_b0525","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1111\/j.1476-5381.2009.00190.x","article-title":"Therapeutic antibodies: successes, limitations and hopes for the future","volume":"157","author":"Chames","year":"2009","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.intimp.2024.113544_b0530","doi-asserted-by":"crossref","unstructured":"N.A. Kennedy, G.A. Heap, H.D. Green, B. Hamilton, C. Bewshea, G.J. Walker, A. Thomas, R. Nice, M.H. Perry, S. Bouri, N. Chanchlani, N.M. Heerasing, P. Hendy, S. Lin, D.R. Gaya, J.R.F. Cummings, C.P. Selinger, C.W. Lees, A.L. Hart, M. Parkes, S. Sebastian, J.C. Mansfield, P.M. Irving, J. Lindsay, R.K. Russell, T.J. McDonald, D. McGovern, J.R. Goodhand, T. Ahmad, V. Patel, Z. Mazhar, R. Saich, B. Colleypriest, T.C. Tham, T.H. Iqbal, V. Kaushik, S. Murugesan, S. Singh, S. Weaver, C. Preston, A. Butt, M. Smith, D. Basude, A. Beale, S. Langlands, N. Direkze, M. Parkes, F. Torrente, J. De La Revella Negro, C.E. MacDonald, S.M. Evans, A.V.J. Gunasekera, A. Thakur, D. Elphick, A. Shenoy, C.U. Nwokolo, A. Dhar, A.T. Cole, A. Agrawal, S. Bridger, J. Doherty, S.C. Cooper, S. De Silva, C. Mowat, P. Mayhead, C. Lees, G. Jones, T. Ahmad, J.W. Hart, D.R. Gaya, R.K. Russell, L. Gervais, P. Dunckley, T. Mahmood, P.J.R. Banim, S. Sonwalkar, D. Ghosh, R.H. Phillips, A. Azaz, S. Sebastian, R. Shenderey, L. Armstrong, C. Bell, R. Hariraj, H. Matthews, H. Jafferbhoy, C.P. Selinger, V. Zamvar, J.S. De Caestecker, A. Willmott, R. Miller, P.S. Babu, C. Tzivinikos, S.L. Bloom, G. Chung-Faye, N.M. Croft, J.M. Fell, M. Harbord, A. Hart, B. Hope, P.M. Irving, J.O. Lindsay, J.E. Mawdsley, A. McNair, K.J. Monahan, C.D. Murray, T. Orchard, T. Paul, R. Pollok, N. Shah, S. Bouri, M.W. Johnson, A. Modi, K.D. Kabiru, B.K. Baburajan, B. Bhaduri, A.A. Fagbemi, S. Levison, J.K. Limdi, G. Watts, S. Foley, A. Ramadas, G. MacFaul, J. Mansfield, L. Grellier, M.-A. Morris, M. Tremelling, C. Hawkey, S. Kirkham, C.P. Charlton, A. Rodrigues, A. Simmons, S.J. Lewis, J. Snook, M. Tighe, P.M. Goggin, A.N. De Silva, S. Lal, M.S. Smith, S. Panter, J.R.F. Cummings, S. Dharmisari, M. Carter, D. Watts, Z. Mahmood, B. McLain, S. Sen, A.J. Pigott, D. Hobday, E. Wesley, R. Johnston, C. Edwards, J. Beckly, D. Vani, S. Ramakrishnan, R. Chaudhary, N.J. Trudgill, R. Cooney, A. Bell, N. Prasad, J.N. Gordon, M.J. Brookes, A. Li, S. Gore, Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn\u2019s disease: a prospective, multicentre, cohort study, The Lancet Gastroenterology & Hepatology 4 (2019) 341\u2013353. Doi: 10.1016\/S2468-1253(19)30012-3.","DOI":"10.1016\/S2468-1253(19)30012-3"},{"key":"10.1016\/j.intimp.2024.113544_b0535","unstructured":"LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-. Infliximab. [Updated 2017 Feb 10]., n.d."},{"key":"10.1016\/j.intimp.2024.113544_b0540","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1177\/2040622315586970","article-title":"Vedolizumab: an \u03b14\u03b27 integrin antagonist for ulcerative colitis and Crohn\u2019s disease","volume":"6","author":"Cherry","year":"2015","journal-title":"Therapeutic Advances in Chronic Disease"},{"key":"10.1016\/j.intimp.2024.113544_b0545","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1136\/annrheumdis-2020-219012","article-title":"JAK selectivity and the implications for clinical inhibition of pharmacodynamic cytokine signalling by filgotinib, upadacitinib, tofacitinib and baricitinib","volume":"80","author":"Traves","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.intimp.2024.113544_b0550","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1080\/14656566.2019.1659778","article-title":"The pharmacotherapeutic management of pediatric Crohn\u2019s disease","volume":"20","author":"Zimmerman","year":"2019","journal-title":"Expert Opin. Pharmacother."},{"key":"10.1016\/j.intimp.2024.113544_b0860","doi-asserted-by":"crossref","first-page":"984","DOI":"10.3390\/genes10120984","article-title":"Transcriptional regulation of INSR, the insulin receptor gene","volume":"10","author":"Payankaulam","year":"2019","journal-title":"Genes"},{"key":"10.1016\/j.intimp.2024.113544_b0865","doi-asserted-by":"crossref","first-page":"A208","DOI":"10.1136\/gut.2011.239301.438","article-title":"Inflammatory bowel disease is more common in type 1 diabetes mellitus","volume":"60","author":"Leeds","year":"2011","journal-title":"Gut"},{"key":"10.1016\/j.intimp.2024.113544_b0870","first-page":"125","article-title":"The relationship between inflammatory bowel disease and type 1 diabetes mellitus: a study of relative prevalence in comparison with population controls","volume":"24","author":"Penny","year":"2015","journal-title":"J. Gastrointestin. Liver Dis."},{"key":"10.1016\/j.intimp.2024.113544_b0875","unstructured":"EnteroTarget ApS, (n.d.). http:\/\/enterotarget.com\/ (accessed August 26, 2023)."},{"key":"10.1016\/j.intimp.2024.113544_b0880","article-title":"Nothing makes us happier at Bioneer A\/S than helping clients bring their\u2026","author":"Bioneer A\/S on LinkedIn","year":"2023","journal-title":"(n.d.)"},{"key":"10.1016\/j.intimp.2024.113544_b0885","unstructured":"EnteroTarget on LinkedIn: #collaboration #bioneer #ulcerativecolitis #ibd #insulin, (n.d.). https:\/\/www.linkedin.com\/posts\/enterotarget_collaboration-bioneer-ulcerativecolitis-activity-7006964752841068545-3SWl?trk=public_profile_like_view (accessed October 6, 2023)."},{"key":"10.1016\/j.intimp.2024.113544_b0890","unstructured":"EnteroTarget on LinkedIn: #collaboration #bioneer #ulcerativecolitis #ibd #insulin #capsule\u2026, (n.d.). https:\/\/www.linkedin.com\/feed\/update\/urn:li:activity:7095422205370462208\/ (accessed October 6, 2023)."},{"key":"10.1016\/j.intimp.2024.113544_b0895","first-page":"371","article-title":"Intestinal insulin\/IGF1 signalling through FoxO1 regulates epithelial integrity and susceptibility to colon cancer, Nature","volume":"1","author":"Ostermann","year":"2019","journal-title":"Metabolism"},{"key":"10.1016\/j.intimp.2024.113544_b0900","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1093\/ecco-jcc\/jjaa136","article-title":"Metformin use is associated with a lower risk of inflammatory bowel disease in patients with type 2 diabetes mellitus","volume":"15","author":"Tseng","year":"2021","journal-title":"Journal of Crohn\u2019s and Colitis"},{"key":"10.1016\/j.intimp.2024.113544_b0905","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1186\/s12967-023-04214-3","article-title":"Insulin alleviates murine colitis through microbiome alterations and bile acid metabolism","volume":"21","author":"He","year":"2023","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.intimp.2024.113544_b0910","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1002\/1097-0142(199007\/08)14:4<889::AID-CNCR2820140428>3.0.CO;2-L","article-title":"Urokinase excretion in patients with carcinoma","volume":"14","author":"Riggenbach","year":"1961","journal-title":"Cancer"},{"key":"10.1016\/j.intimp.2024.113544_b0915","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1083\/jcb.100.1.86","article-title":"A cellular binding site for the Mr 55,000 form of the human plasminogen activator, urokinase","volume":"100","author":"Vassalli","year":"1985","journal-title":"J Cell Biol"},{"key":"10.1016\/j.intimp.2024.113544_b0920","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1083\/jcb.115.4.1107","article-title":"In vivo paracrine interaction between urokinase and its receptor: effect on tumor cell invasion","volume":"115","author":"Ossowski","year":"1991","journal-title":"J Cell Biol"},{"key":"10.1016\/j.intimp.2024.113544_b0925","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1038\/nrm977","article-title":"uPAR: a versatile signalling orchestrator","volume":"3","author":"Blasi","year":"2002","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.intimp.2024.113544_b0930","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/j.biocel.2006.10.008","article-title":"Urokinase-type plasminogen activator","volume":"39","author":"Crippa","year":"2007","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"10.1016\/j.intimp.2024.113544_b0935","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1186\/s12967-022-03329-3","article-title":"Urokinase-type plasminogen activator receptor (uPAR) as a therapeutic target in cancer","volume":"20","author":"Zhai","year":"2022","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.intimp.2024.113544_b0940","unstructured":"1885-1948: Innovative beginnings | Boehringer Ingelheim, (n.d.). https:\/\/www.boehringer-ingelheim.com\/about-us\/history\/1885-1948-innovative-beginnings (accessed August 27, 2023)."},{"key":"10.1016\/j.intimp.2024.113544_b0945","unstructured":"B. Ingelheim, Sites Around the World, Boehringer Ingelheim (2021). https:\/\/www.boehringer-ingelheim.com\/sites-around-world (accessed August 27, 2023)."},{"key":"10.1016\/j.intimp.2024.113544_b0950","unstructured":"B. Ingelheim, 1948-1990: Going global, Boehringer Ingelheim (2022). https:\/\/www.boehringer-ingelheim.com\/about-us\/history\/1948-1990-going-global (accessed August 28, 2023)."},{"key":"10.1016\/j.intimp.2024.113544_b0955","doi-asserted-by":"crossref","first-page":"2899","DOI":"10.1038\/s41598-023-29824-1","article-title":"Urokinase-type plasminogen activator blockade ameliorates experimental colitis in mice","volume":"13","author":"Kida","year":"2023","journal-title":"Sci Rep"},{"key":"10.1016\/j.intimp.2024.113544_b0960","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/0092-8674(95)90530-8","article-title":"Identification of a nuclear receptor that is activated by farnesol metabolites","volume":"81","author":"Forman","year":"1995","journal-title":"Cell"},{"key":"10.1016\/j.intimp.2024.113544_b0965","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/S1097-2765(00)00050-2","article-title":"Molecular basis for feedback regulation of bile acid synthesis by nuclear receptors","volume":"6","author":"Lu","year":"2000","journal-title":"Mol. Cell"},{"key":"10.1016\/j.intimp.2024.113544_b0970","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S1097-2765(00)00051-4","article-title":"A regulatory cascade of the nuclear receptors FXR, SHP-1, and LRH-1 represses bile acid biosynthesis","volume":"6","author":"Goodwin","year":"2000","journal-title":"Mol. Cell"},{"key":"10.1016\/j.intimp.2024.113544_b0975","first-page":"2148","article-title":"Farnesoid X receptor (FXR): Structures and ligands, Computational and Structural","volume":"19","author":"Jiang","year":"2021","journal-title":"Biotechnol. J."},{"key":"10.1016\/j.intimp.2024.113544_b0980","doi-asserted-by":"crossref","unstructured":"J.K. Kemper, Regulation of FXR transcriptional activity in health and disease: Emerging roles of FXR cofactors and post-translational modifications, Biochimica Et Biophysica Acta (BBA)-Molecular Basis of Disease 1812 (2011) 842\u2013850.","DOI":"10.1016\/j.bbadis.2010.11.011"},{"key":"10.1016\/j.intimp.2024.113544_b0985","first-page":"G108","article-title":"FXR agonist GW4064 improves liver and intestinal pathology and alters bile acid metabolism in rats undergoing small intestinal resection, American Journal of Physiology-Gastrointestinal and Liver","volume":"317","author":"Cao","year":"2019","journal-title":"Physiology"},{"key":"10.1016\/j.intimp.2024.113544_b0990","doi-asserted-by":"crossref","first-page":"8868","DOI":"10.1021\/acs.jafc.9b03173","article-title":"Chenodeoxycholic Acid (CDCA) Protects against the Lipopolysaccharide-Induced Impairment of the Intestinal Epithelial Barrier Function via the FXR-MLCK Pathway","volume":"67","author":"Song","year":"2019","journal-title":"J. Agric. Food Chem."},{"key":"10.1016\/j.intimp.2024.113544_b0995","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1038\/s12276-023-00932-2","article-title":"The role of the farnesoid X receptor in kidney health and disease: a potential therapeutic target in kidney diseases","volume":"55","author":"Kim","year":"2023","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.intimp.2024.113544_b1000","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1065790","article-title":"Stimulation of the farnesoid X receptor promotes M2 macrophage polarization","volume":"14","author":"Jaroonwitchawan","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2024.113544_b1005","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2020.173090","article-title":"Macrophage M1\/M2 polarization","volume":"877","author":"Yunna","year":"2020","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.intimp.2024.113544_b1010","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.632864","article-title":"Bile acids elevated in chronic periaortitis could activate farnesoid-X-receptor to suppress IL-6 production by macrophages","volume":"12","author":"Cao","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2024.113544_b1015","doi-asserted-by":"crossref","DOI":"10.1016\/j.mce.2022.111678","article-title":"Recent advances on FXR-targeting therapeutics","volume":"552","author":"Panzitt","year":"2022","journal-title":"Mol. Cell. Endocrinol."},{"key":"10.1016\/j.intimp.2024.113544_b1020","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.1038\/s41598-020-58644-w","article-title":"Attenuation of bile acid-mediated FXR and PXR activation in patients with Crohn\u2019s disease","volume":"10","author":"Wilson","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.intimp.2024.113544_b1025","article-title":"Farnesoid-X receptor as a therapeutic target for inflammatory bowel disease and colorectal cancer","volume":"13","author":"Zhou","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.intimp.2024.113544_b1030","doi-asserted-by":"crossref","first-page":"3920","DOI":"10.1073\/pnas.0509592103","article-title":"Regulation of antibacterial defense in the small intestine by the nuclear bile acid receptor","volume":"103","author":"Inagaki","year":"2006","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.intimp.2024.113544_b1035","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1038\/s41374-020-0439-y","article-title":"Enhanced alcoholic liver disease in mice with intestine-specific farnesoid X receptor deficiency","volume":"100","author":"Huang","year":"2020","journal-title":"Lab. Invest."},{"key":"10.1016\/j.intimp.2024.113544_b1040","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1093\/bmb\/ldaa006","article-title":"Obeticholic acid\u2014a new therapy in PBC and NASH","volume":"133","author":"Chapman","year":"2020","journal-title":"Br. Med. Bull."},{"key":"10.1016\/j.intimp.2024.113544_b1045","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1053\/j.gastro.2023.03.213","article-title":"Next-Generation Farnesoid X Receptor Agonists in NASH Treatment: Are We There Yet?","volume":"165","author":"DeBosch","year":"2023","journal-title":"Gastroenterology"},{"key":"10.1016\/j.intimp.2024.113544_b1050","doi-asserted-by":"crossref","unstructured":"Jean-Fran\u00e7ois Dufour, Quentin M Anstee, Elisabetta Bugianesi, Stephen Harrison, Rohit Loomba, Valerie Paradis, Herbert Tilg, Vincent Wai-Sun Wong, Shira Zelber-sagi, Current therapies and new developments in NASH, Gut 71 (2022) 2123. Doi: 10.1136\/gutjnl-2021-326874.","DOI":"10.1136\/gutjnl-2021-326874"},{"key":"10.1016\/j.intimp.2024.113544_b1055","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.jhep.2021.10.018","article-title":"EDP-305 in patients with NASH: A phase II double-blind placebo-controlled dose-ranging study","volume":"76","author":"Ratziu","year":"2022","journal-title":"J. Hepatol."},{"key":"10.1016\/j.intimp.2024.113544_b1060","doi-asserted-by":"crossref","DOI":"10.1002\/hep.31205","article-title":"Cilofexor, a Nonsteroidal FXR Agonist, in Patients With Noncirrhotic NASH: A Phase 2 Randomized Controlled Trial","volume":"72","author":"Patel","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.intimp.2024.113544_b1065","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1038\/s41591-022-02200-8","article-title":"Tropifexor for nonalcoholic steatohepatitis: An adaptive, randomized, placebo-controlled phase 2a\/b trial","volume":"29","author":"Sanyal","year":"2023","journal-title":"Nat. Med."},{"key":"10.1016\/j.intimp.2024.113544_b1070","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1038\/nm.3760","article-title":"Intestinal FXR agonism promotes adipose tissue browning and reduces obesity and insulin resistance","volume":"21","author":"Fang","year":"2015","journal-title":"Nat. Med."},{"key":"10.1016\/j.intimp.2024.113544_b1075","doi-asserted-by":"crossref","first-page":"e3594","DOI":"10.1002\/dmrr.3594","article-title":"Brown adipose tissue and regulation of human body weight","volume":"39","author":"Harb","year":"2023","journal-title":"Diabetes Metab. Res. Rev."},{"key":"10.1016\/j.intimp.2024.113544_b1080","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1073\/pnas.1323977111","article-title":"Farnesoid X receptor (FXR) gene deficiency impairs urine concentration in mice","volume":"111","author":"Zhang","year":"2014","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.intimp.2024.113544_b1085","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1002\/hep.31205","article-title":"Cilofexor, a Nonsteroidal FXR Agonist, in Patients With Noncirrhotic NASH: A Phase 2 Randomized Controlled Trial","volume":"72","author":"Patel","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.intimp.2024.113544_b1090","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1038\/s41598-020-58562-x","article-title":"Obeticholic acid and INT-767 modulate collagen deposition in a NASH in vitro model","volume":"10","author":"Anfuso","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.intimp.2024.113544_b1095","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.113380","article-title":"Farnesoid X receptor activation by the novel agonist TC-100 (3\u03b1, 7\u03b1, 11\u03b2-Trihydroxy-6\u03b1-ethyl-5\u03b2-cholan-24-oic Acid) preserves the intestinal barrier integrity and promotes intestinal microbial reshaping in a mouse model of obstructed bile acid flow","volume":"153","author":"Marzano","year":"2022","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.intimp.2024.113544_b1100","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.2174\/1568026614666141112094430","article-title":"Knocking on FXR\u2019s door: the \u201chammerhead\u201d-structure series of FXR agonists - amphiphilic isoxazoles with potent in vitro and in vivo activities","volume":"14","author":"Gege","year":"2014","journal-title":"Curr Top Med Chem"},{"key":"10.1016\/j.intimp.2024.113544_b1105","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1080\/13543784.2020.1763302","article-title":"Bile acid modulators for the treatment of nonalcoholic steatohepatitis","volume":"29","author":"Fiorucci","year":"2020","journal-title":"Expert Opin. Invest. Drugs"},{"key":"10.1016\/j.intimp.2024.113544_b1110","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1111\/apt.15967","article-title":"Randomised clinical trial: significant biochemical and colonic transit effects of the farnesoid X receptor agonist tropifexor in patients with primary bile acid diarrhoea","volume":"52","author":"Camilleri","year":"2020","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.intimp.2024.113544_b1115","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhepr.2022.100544","article-title":"Farnesoid X receptor agonist tropifexor attenuates cholestasis in a randomised trial in patients with primary biliary cholangitis","volume":"4","author":"Schramm","year":"2022","journal-title":"JHEP Reports"},{"key":"10.1016\/j.intimp.2024.113544_b1120","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.jhep.2009.03.025","article-title":"Farnesoid X receptor agonist WAY-362450 attenuates liver inflammation and fibrosis in murine model of non-alcoholic steatohepatitis","volume":"51","author":"Zhang","year":"2009","journal-title":"J. Hepatol."},{"key":"10.1016\/j.intimp.2024.113544_b1125","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/nrendo.2015.4","article-title":"Gut-specific FXR agonism","volume":"11","author":"Os\u00f3rio","year":"2015","journal-title":"Nat. Rev. Endocrinol."},{"key":"10.1016\/j.intimp.2024.113544_b1130","doi-asserted-by":"crossref","first-page":"3868","DOI":"10.1021\/acs.jmedchem.9b01621","article-title":"Nidufexor (LMB763), a Novel FXR Modulator for the Treatment of Nonalcoholic Steatohepatitis","volume":"63","author":"Chianelli","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.intimp.2024.113544_b1135","unstructured":"Gannex Pharma Co., Ltd., A Phase 1, Open-label, Single-dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ASC43F, a Fixed-dose Combination (FDC) Oral Tablet Containing ASC41, a THR \u03b2 Agonist and ASC42, an FXR Agonist in Healthy Subjects, clinicaltrials.gov, 2021. https:\/\/clinicaltrials.gov\/study\/NCT05118516 (accessed January 1, 2024)."},{"key":"10.1016\/j.intimp.2024.113544_b1140","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1007\/s40268-023-00444-4","article-title":"Human Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ASC42, a Novel Farnesoid X Receptor Agonist","volume":"23","author":"He","year":"2023","journal-title":"Drugs R&D"},{"key":"10.1016\/j.intimp.2024.113544_b1145","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jhep.2021.01.047","article-title":"A structurally optimized FXR agonist, MET409, reduced liver fat content over 12 weeks in patients with non-alcoholic steatohepatitis","volume":"75","author":"Harrison","year":"2021","journal-title":"J. Hepatol."},{"key":"10.1016\/j.intimp.2024.113544_b1150","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1002\/hep.30509","article-title":"The Nonsteroidal Farnesoid X Receptor Agonist Cilofexor (GS-9674) Improves Markers of Cholestasis and Liver Injury in Patients With Primary Sclerosing Cholangitis","volume":"70","author":"Trauner","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.intimp.2024.113544_b1155","unstructured":"History of Salk - Salk Institute for Biological Studies, (n.d.). https:\/\/www.salk.edu\/about\/history-of-salk\/ (accessed September 3, 2023)."},{"key":"10.1016\/j.intimp.2024.113544_b1160","unstructured":"Memoriam - Salk Institute for Biological Studies, (n.d.). https:\/\/www.salk.edu\/about\/history-of-salk\/in-memoriam\/ (accessed September 3, 2023)."},{"key":"10.1016\/j.intimp.2024.113544_b1165","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2213041119","article-title":"FXR mediates ILC-intrinsic responses to intestinal inflammation","volume":"119","author":"Fu","year":"2022","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.intimp.2024.113544_b1170","unstructured":"Salk scientists develop compound that reverses gut inflammation in mice - Salk Institute for Biological Studies, (n.d.). https:\/\/www.salk.edu\/news-release\/salk-scientists-develop-compound-that-reverses-gut-inflammation-in-mice\/ (accessed September 3, 2023)."},{"key":"10.1016\/j.intimp.2024.113544_b1175","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1038\/sj.emboj.7600635","article-title":"Crystal structure of the human urokinase plasminogen activator receptor bound to an antagonist peptide","volume":"24","author":"Llinas","year":"2005","journal-title":"EMBO J."},{"key":"10.1016\/j.intimp.2024.113544_b1180","unstructured":"B. Eiseman, W. Silen, B. GS, K. AJ, Fecal enema as an adjunct in the treatment of pseudomembranous enterocolitis., Surgery 44 (1958) 854\u2013859."},{"key":"10.1016\/j.intimp.2024.113544_b1185","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/S0140-6736(89)91183-5","article-title":"Treatment of ulcerative colitis by implantation of normal colonic flora","volume":"333","author":"Bennet","year":"1989","journal-title":"Lancet"},{"key":"10.1016\/j.intimp.2024.113544_b1190","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1007\/s00535-019-01618-1","article-title":"Manipulating resident microbiota to enhance regulatory immune function to treat inflammatory bowel diseases","volume":"55","author":"Mishima","year":"2020","journal-title":"J. Gastroenterol."},{"key":"10.1016\/j.intimp.2024.113544_b1195","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2021.119622","article-title":"Restoration of dysbiotic human gut microbiome for homeostasis","volume":"278","author":"Dixit","year":"2021","journal-title":"Life Sci."},{"key":"10.1016\/j.intimp.2024.113544_b1200","first-page":"1303","article-title":"Practical use of RBX2660 for the prevention of recurrent Clostridioides difficile infection","volume":"118","author":"Feuerstadt","year":"2023","journal-title":"Off. J. Am. College Gastroenterol|ACG"},{"key":"10.1016\/j.intimp.2024.113544_b1205","unstructured":"US Food and Drug Administration, FDA approves first fecal microbiota product, (2023)."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576924020666?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576924020666?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T11:33:20Z","timestamp":1789644800000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576924020666"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":241,"alternative-id":["S1567576924020666"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2024.113544","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Novel targets for mucosal healing in inflammatory bowel disease therapy","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2024.113544","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"113544"}}